(The 3rd CIIE) Opportunities for CIIE: Many pharmaceutical companies bring their latest achievements to the "CIIE" to help healthy life
China News Service, Shanghai, November 9th (Reporter Liu Xu) During the third CIIE, in the high-profile biomedicine field, AstraZeneca, Novartis, Medtronic, Pfizer, Takeda Pharmaceuticals, Eli Lilly China, Fosun Global pharmaceutical companies such as pharmaceuticals have brought their innovative achievements to the exhibition.
Data map: The medical equipment and medicine and health care exhibition area is the most "hot" exhibition area of the 3rd CIIE. Among the more than 300 exhibiting companies, more than 70 are the world's top 500 companies and industry leaders.
Among them, 90% of the world's top 500 pharmaceutical companies came to the exhibition.
Photo by Tang Yanjun
Pfizer exhibited at this year’s exhibition with the concept of “Science to Win” and demonstrated its breakthrough innovations, leading R&D and global supply chain, and powerful products in the five fields of tumors, vaccines, rare diseases, inflammation and immunity, and anti-infection. In the main booth, the heavy new products Weiwanxin, Bebosa, Loratinib, and Sutanmin attracted much attention.
Pierre Gaudreault, Acting President of Pfizer Biopharmaceutical Group in China, said: "Since Pfizer entered China in the 1980s, it has accompanied the Chinese medical and health industry for more than 30 years. At present, China is the world's second largest pharmaceutical market and Pfizer is one of the most important markets in the world. Pfizer looks forward to further demonstrating its innovative achievements at the third CIIE, opening up cooperation, and working with all partners to create a bright future for'Healthy China 2030'!"
Takeda Pharmaceutical showcased 5 new rare disease drugs at the CIIE, covering many rare diseases such as Fabry disease, hereditary angioedema, Gaucher disease, hemophilia and so on.
At the CIIE event site, Takeda China and the China Red Cross Foundation also jointly launched the country's first public welfare project for the care of patients with inflammatory bowel disease (IBD)-"Changxiang·Online Care Center for the Whole Disease".
"The broad platform of the CIIE has allowed countries, industries, and companies to showcase cutting-edge technologies and innovative products, and promote the integration of global trade and innovation, fully demonstrating the government's determination to promote common openness and promote innovative development." Takeda Pharmaceutical Global Shan Guohong, Senior Vice President and President of Takeda China, said, “As a multinational pharmaceutical company focusing on R&D and innovation, we look forward to the CIIE to showcase Takeda’s innovative drugs and breakthrough therapies in the core therapeutic field, and introduce more innovative drugs at a faster rate. Many international cutting-edge drugs have helped Chinese patients obtain a globally synchronized treatment experience, so that Chinese patients with rare diseases can be treated with medicine and return to a healthy life."
In the previous two CIIEs, Medtronic brought the world's smallest pacemaker, ushering in a new era of leadless pacing therapy.
At this CIIE, Medtronic continues to pay attention to the needs of local patients in China, especially in the field of pacing therapy, and brings more innovative, high-quality, and accessible medical solutions, such as the world’s smallest pacemaker, the new generation MicraAV in Boao. Try it first, and a 3T NMR compatible pacemaker that meets the current clinical diagnosis needs.
Lin Song, Vice President of Medtronic's Greater China Cardio and Vascular Business Group, said: "The'Jinbo effect' continues to overflow in the medical field. This is a major practical breakthrough and innovation in China's opening up. It has allowed many multinational companies like Medtronic to see China. Adhering to an open and win-win attitude also strengthens Medtronic's determination to continue to take root in China, cultivate China in depth, and benefit China."
Leveraging on the open and win-win platform of the CIIE, Eli Lilly China held the "Drug Innovation Summit Forum and the Award Ceremony for Strategic Cooperation in Clinical Trials", announcing that it had reached strategic cooperation in clinical trials with West China Hospital of Sichuan University and Xiangya Hospital of Central South University to meet the needs of China The increasing demand for clinical trials has helped improve the clinical trial level of partner institutions and jointly promote the upgrading of China's clinical trial ecosystem.
Dr. Wang Li, Senior Vice President of Eli Lilly China and head of the Center for Drug Development and Medical Affairs, said: “Thanks to a series of policy dividends from regulatory authorities, Eli Lilly’s drug R&D is achieving accelerated development in China. The future development of pharmaceutical innovation is full of confidence, and we look forward to Chinese patients getting the latest drugs in sync with the world, which will bring clinical benefits." (End)